Exchange: NASDAQ·Updated 04:15 PM EST

ANGO News

News
all
press releases
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
ANGO's strong NanoKnife sales, expanding Med Tech portfolio and solid fiscal Q1 results support growth prospects, despite tariff and inflation pressures.
Zacks
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
ANGO's strong NanoKnife sales, expanding Med Tech portfolio and solid fiscal Q1 results support growth prospects, despite tariff and inflation pressures.
Zacks
More News
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the bodys vascular system, expanding cancer treatment options and improving patient quality of life, today announced the grant of inducement awards to Eric Honroth...
Business Wire
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the bodys vascular system, expanding cancer treatment options and improving patient quality of life, today announced that its management is scheduled to participate...
Business Wire
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the bodys vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced two milestones for irreversible...
Business Wire
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the bodys vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Humana has updated its Medicare...
Business Wire
AngioDynamics beats first-quarter earnings estimates as revenues rise 6.9% on strong Med Tech growth, with margin expansion and robust Auryon and NanoKnife sales.
Zacks
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
ANGO stock drops 21% as AngioDynamics reports Q1 results, names Eric Honroth as new CEO, and reaffirms FY27 guidance.read more...
Benzinga
Key PointsAngioDynamics beat on both top and bottom lines this morning...
Nasdaq News: Markets
(RTTNews) - While reporting financial results for the first quarter on Thursday, medical technology company AngioDynamics, Inc. (ANGO) reiterated its adjusted loss and net sales guidance for the full year 2027, based on its first quarter performance and current outlook for the re...
Nasdaq News: Markets

Advertisement|Remove ads.